In this case, we innovatively adopted the treatment regimen of anlotinib combined with EP in the transformation of SCLC after resistance to EGFR TKIs therapy, and the PFS reached 10.1 months, which was a longer PFS compared with the data from previous case reports and retrospective analyses, suggesting that the anlotinib combined with EP regimen could be the first choice of treatment after transformation to SCLC. This evidence concerns the gene EGFR and small cell lung carcinoma.